Indoco Remedies Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2q19rq7y79k9qs3uvh91adcn.pdf

Key Takeaways


Domestic Business: Prescriptions Outrun Sales

Aditi Panandikar: "It gives me great joy to announce that after almost six quarters, we are in positive in this quarter for performance."

International Formulations: The Quarter's Engine

Aditi Panandikar: "The whole purpose of being on ground in U.K. is to be able to get more margin and not lose it so, if we see that the market is not opportune on price front then we hold."

Subsidiary Health: FPP and Warren Remedies

Aditi Panandikar: "It is the API CAPEX done and the operating cost at API level from where we are really not able to sell anything right now because most products are under validation."

Balance Sheet & Liquidity


Strategic Moves & Plant Resolution

Aditi Panandikar: "This move was made in the interest of our wonderful brands and portfolios which should now get the requisite attention they deserve and therefore grow. This hive off would also help us at Indoco focus on areas of strength and those which are our core areas for growing the ethical business."

Guidance & Commitments

CommitmentSpecificsTimeline
Debt reductionRepay ₹140 crore per year, aim to prepay a little moreNext 3 years
CAPEX restraintNo major CAPEX plannedNext 2 years
MSME dues settlementConfident of settling duesWithin a week of the call
India business growthExpected in line with IPMOngoing
Warren API turnaroundReg market approval expectedAbout one more year
Warren API near-termTurnaround likely to take a couple more quartersCouple of quarters
US/Europe liquid oral launchesLaunch liquid orals in less crowded spaceComing year
FPP extraordinary cost impactShould reduce going forwardForward-looking

Key Metrics

MetricQ4 FY26
Standalone net revenue₹429.1 cr, +25.8% YoY and +10.1% QoQ
Consolidated net revenue₹455.9 cr, +18.8% YoY and +5% QoQ
Standalone EBITDA margin14.7% (₹63 cr), vs 1% (₹3.5 cr) YoY and 6.6% (₹25.9 cr) QoQ
Consolidated EBITDA margin10.9% (₹49.7 cr), vs -0.2% (-₹0.8 cr) YoY and 7.3% (₹31.5 cr) QoQ
Domestic formulation revenue₹173.9 cr, vs ₹185.1 cr YoY
International formulation revenue₹214.7 cr, +94.6% YoY
Regulated markets revenue₹140.1 cr, +78.3% YoY
US business revenue₹54.6 cr, +77.5% YoY
Europe revenue₹78.6 cr, +68.7% YoY
South Africa, Australia and New Zealand revenue₹69.2 cr, vs ₹12.2 cr YoY
Emerging markets revenue₹74.6 cr, +134% YoY
API business revenue₹31.5 cr, -23% YoY
Services revenue (AnaCipher CRO and Indoco Analytical Solutions)₹89.5 cr, +65.3% YoY
Consolidated debt~₹960 cr, long-term ₹620 cr, short-term ₹344 cr; flat vs March '25
Debt repayment commitment for FY27₹140 cr, with similar amounts each year for next 3 years
Average interest rate on borrowings8.5% to 9%
Forex loss on ECB loan₹24 cr impact on finance cost
OTC (Warren) revenue₹27.4 cr for Q4; ₹120 cr for full year
New launch contribution (India)>₹2 cr for Q4; ₹20 cr for full year
Ophthal division India primary sales (full year)₹37 cr